Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Monsanto, OSU, DuPont, and More


Title: Method of Diagnosing Poor-survival-prognosis Colon Cancer Using miR-16b

Patent Number: 8,518,647

Filed: Nov. 14, 2011

Lead Inventor: Carlo Croce, Ohio State University

The invention, the patent's abstract states, provides "novel methods and compositions for the diagnosis and treatment of colon cancers … in particular … diagnostics and prognostics for colon including colon adenocarcinoma cancer patients wherein … methods related to measuring miR levels can [be used to] predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis."

Title: Use of RNAi Technology to Inhibit ASIC3

Patent Number: 8,518,902

Filed: Jan. 31, 2011

Lead Inventor: Kathleen Sluka, University of Iowa

"In vitro studies using cells transfected with acid-sensing ion channel 3 or acid-sensing ion channel 1 cDNA demonstrated that … miRNAs against mouse ASIC3 selectively inhibit mouse ASIC3, but not ASIC1, as detected by protein expression and responses to pH," the patent's abstract states. "When ... miR-844 or miR-847 were used in vivo, delivered into the muscle of mice using a replication-defective herpes simplex viral vector, primary and secondary hyperalgesia were reduced after carrageenan-induced muscle inflammation. Accordingly, the … invention provides RNAi agents that target ASIC3, methods of preparing such RNAi agents, and methods of using them to modulate in a cell the level of ASIC3 or activity of an ASIC including at least one ASIC3. Modulation of ASIC3 activity or levels can be used for different purposes such as treating pain associated with the expression of ASIC3 and the like."

Title: RNA Interference-Mediated Inhibition of Catenin, Beta 1 Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 8,518,907

Filed: Aug. 2, 2011

Lead Inventor: Duncan Brown, Merck

The invention, the patent's abstract states, "relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules … capable of mediating or that mediate RNA interference against CTNNB1 gene expression."

Title: RIP140 Regulation of Glucose Transport

Patent Number: 8,519,118

Filed: Jan. 6, 2012

Lead Inventor: Michael Czech, University of Massachusetts

"Inhibition of RIP140 increases glucose transport," according to the patent's abstract. "Compounds that inhibit RIP140 expression or activity are useful for treating disorders associated with aberrant glucose transport, treating obesity, increasing metabolism, and increasing brown fat." Such compounds specifically include siRNAs, the patent notes.

Title: Identification and Use of Target Genes for Control of Plant Parasitic Nematodes

Patent Number: 8,519,225

Filed: Feb. 9, 2007

Lead Inventor: Andrey Boukharov, Monsanto

"The invention relates to identifying and evaluating target coding sequences for control of plant parasitic nematodes by inhibiting one or more biological functions, and their use," the patent's abstract states. "The invention provides methods and compositions for identification of such sequences and for the control of a plant-parasitic nematode population. By feeding one or more recombinant double stranded RNA molecules provided by the invention to the nematode, a reduction in disease may be obtained through suppression of nematode gene expression. The invention is also directed to methods for making transgenic plants that express the double-stranded RNA molecules, and the plant cells and plants obtained thereby."

Title: Targeted Intracellular Delivery of Antiviral Agents

Application Number: 20130216612

Filed: May 2, 2013

Inventor: Pieter Jaap Gaillard, BBB Holding

"The invention relates to methods of targeted drug delivery of antiviral compounds, including chemical agents and nucleic acid-based drugs" including siRNAs, the patent application's abstract states. "Furthermore, the invention relates to targeted drug delivery of antiviral compounds to intracellular target sites within cells, tissues, and organs, in particular to target sites within the central nervous system, into and across the blood-brain barrier, by targeting to internalizing uptake receptors present on these cells, tissues, and organs. Thereto, the antiviral compounds, or the pharmaceutical acceptable carrier thereof, are conjugated to ligands that facilitate the specific binding to and internalization by these receptors."

Title: Polynucleotides for Reducing Respiratory Syncytial Virus Gene Expression

Application Number: 20130217751

Filed: Feb. 13, 2013

Lead Inventor: Shyam Mohapatra, University of South Florida

The invention, the patent application's abstract states, pertains to "polynucleotides, such as small interfering RNA, useful for reducing the expression of respiratory syncytial virus genes within a subject; and methods for treating a patient suffering from, or at risk of developing, an RSV infection by administering such polynucleotides to the subject."

Title: Preventative or Therapeutic Agent for Fibrosis

Application Number: 20130217754

Filed: Oct. 14, 2011

Lead Inventor: Esteban Gabazza, Otsuka Pharmaceutical

The patent application, its abstract states, claims an "siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA."

Title: Downregulation of Gene Expression Using Artificial microRNAs for Silencing Fatty Acid Biosynthetic Genes

Application Number: 20130219565

Filed: Jan. 23, 2013

Lead Inventor: Howard Glenn Damude, DuPont

The invention, the patent application's abstract states, relates to "isolated nucleic acid fragments comprising precursor miRNAs, and artificial miRNAs and their use in downregulating gene expression of fatty acid biosynthetic genes."